DSS, Inc. — 2022 Form 10-K Summary
Business context and reporting period
DSS reported for the fiscal year ended December 31, 2022. The company operates nine business lines globally and reports five segments: Product Packaging, Commercial Lending, Direct Marketing, Biotechnology, and Securities and Investment Management. Its businesses range from established packaging and direct sales operations to newer lending, biotech, investment, and digital-asset initiatives.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $47.3 million | $20.3 million |
| Operating loss | $43.7 million | $23.5 million |
| Net loss | $69.7 million | $34.0 million |
| Net loss attributable to common stockholders | $59.8 million | $33.1 million |
| Loss per share, basic and diluted | $0.54 | $0.68 |
| Net cash used in operating activities | $27.0 million | $9.0 million |
- Revenue rose 133%. Direct marketing revenue increased to $22.0 million, largely reflecting SHRG’s inclusion for the full year; printed-products revenue grew 16% to $18.0 million. Rental income was $6.3 million.
- Cost of revenue was $37.5 million, implying gross profit of approximately $9.8 million and a gross margin of about 20.8%. Total costs and expenses reached $91.0 million.
- Significant 2022 items included an $8.75 million litigation settlement loss, $10.7 million in investment losses, a $5.6 million investment impairment, and a $2.8 million fixed-asset impairment. Interest expense was $2.9 million.
- Cash and cash equivalents were $19.3 million, down from $56.6 million. Marketable securities were $27.3 million. Current assets were $48.0 million versus current liabilities of $73.7 million.
- Balance-sheet debt, net, totaled approximately $57.3 million, including $47.2 million classified as current. Scheduled principal payments were $46.9 million in 2023, substantially reflecting the approximately $40.2 million LifeCare loan due in November 2023, which may be extended to November 2024.
- Total assets were $248.9 million, down from $282.7 million in 2021; total equity was $156.7 million. Common shares outstanding increased from approximately 79.7 million to 139.0 million during 2022.
Material changes versus the prior year
- Revenue more than doubled, with much of the increase attributable to consolidating SHRG’s results for all of 2022. The company’s 2022 segment table reports $22.0 million in Direct Marketing revenue and a $40.2 million segment loss.
- Operating and net losses widened, and operating cash outflow increased. Cash fell by $37.3 million during the year.
- Debt and interest costs rose, while the amount of debt due within one year became significant. Marketable securities increased to $27.3 million, but the filing also reports substantial investment-related losses.
- DSS increased its SHRG ownership to approximately 73% by year-end and acquired 75% of Sentinel Brokers in December. It also completed share-based transactions involving related parties and assets, contributing to share-count growth.
Outlook, risks, contingencies, and unusual items
- Management said it would prioritize cost reductions, cash preservation, revenue diversification, and progress toward profitability. The filing provides no formal revenue or earnings guidance.
- Management stated that available cash, marketable securities, and expected note collections could fund operations through March 2024, and concluded substantial doubt about going concern had been alleviated. That assessment also references prospective Impact BioMedical and SHRG fundraising and a possible extension of the LifeCare loan; these are not assured financing sources.
- Management discussed a potential Impact BioMedical IPO and a proposed distribution of four Impact BioMedical shares per DSS share, subject to regulatory and other conditions. The filing does not establish that the IPO or distribution will occur on the stated anticipated timetable.
- Key risks include recurring operating losses and cash burn, substantial near-term debt maturities, investment and intangible-asset impairment risk, reliance on key customers and direct-sales distributors, biotech commercialization and regulatory uncertainty, and possible dilution from future financing. Two customers represented 14% and 6% of 2022 revenue and 36% and 17% of year-end trade receivables.
- The $8.75 million Maiden Biosciences matter was settled; the judgment was vacated and the case dismissed with prejudice. The filing also describes other legal matters and potential contingencies.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing insufficient qualified accounting staff and inadequate documentation of monthly close and reconciliations. Remediation steps were underway but had not yet been fully documented and tested. The auditor gave an unqualified opinion on the financial statements but did not attest to internal-control effectiveness. The 2021 financial statements were restated to correct an inventory error.
- Related-party transactions were significant, including transactions with entities associated with Executive Chairman Heng Fai Ambrose Chan. The filing reports that directors, executive officers, principal stockholders, and affiliates beneficially owned approximately 59% of shares as of March 2023.
Important facts for investors to verify
- Whether DSS can refinance or repay the substantial 2023 debt maturities, especially the LifeCare loan, and whether the stated extension is completed.
- Actual cash availability and realizability of marketable securities and notes receivable, alongside continuing operating cash use and current liabilities.
- Progress and concrete terms for proposed Impact BioMedical and SHRG financings, any IPOs, and the proposed Impact BioMedical share distribution.
- Whether control-remediation measures become effective, and how the 2021 inventory restatement and accounting processes are addressed in later filings.
- Valuation support for goodwill, intangible assets, real estate, and investments, and the effects of customer concentration and related-party dealings.